Shaping the Future of Early Breast Cancer Detection. Our research is focused on developing innovative blood tests to improve early diagnosis and patient outcomes.
The Gap in Detection is Costing Lives
We Aim To Change That
1 in 7
Women in the UK will develop breast cancer in their lifetime.
56,000
New cases detected yearly.
11,500
Deaths in the UK yearly.
Artemis aims to save 1,000+ UK lives annually and up to 5,000+ in the USA with widespread adoption.
50-70
NHS mammography covers women 50–70yrs old only, missing younger women and those with dense breast tissue. Mammography infrastructure is costly, uncomfortable, and under pressure.
65%
of cases are still diagnosed at Stage II or later, often too late for the best outcome.
20mill
Women in the UK remain underserved.
800,000 women don’t attend regular screening clinics, more than 13 million women are under 50yrs and there are 6 million who are between NHS screening rounds.
Breast Density Explained
Who we are.
What we stand for.
Innovation, Health, Humanity
A World-Class Team Driving Artemis from Lab to Patient
A board with a chair who is highly experienced in cancer drug therapies, an experienced entrepreneur (CEO), a professor of mass spectrometry, a professor of oncology, a professor who is a liquid biopsy scientist, an expert in manufacturing, and supported by advisors from NPL, BDO, clinical research organisations and Universities. The team combines commercial, governmental, scientific, and clinical expertise to deliver Artemis from lab to market.
A Visionary Leader Driving Early Detection Forward
With two decades in high-level structured finance and engineering, including senior leadership at GE Capital Europe, Simon Duncan brings commercial discipline and strategic vision to Faster Diagnostics. Grounded in personal conviction and close experience of breast cancer, he founded the company to accelerate earlier detection solutions and now leads Artemis toward clinical adoption — powered by world-class science, data and a clear commitment to improving outcomes through earlier diagnosis.
Simon Duncan
CEO and Co-Founder
.jpg)
Early Detection Changes Everything.
Faster Diagnostics Ltd is a health-tech company developing The ARTEMIS Test® a next-generation non-invasive blood test for the early detection of breast cancer. Using cutting-edge mass spectrometry instrumentation with proscribed statistical pattern recognition learning, Artemis aims to identify cancer-specific molecular patterns in blood plasma before tumours become visible on a mammogram.
The company’s mission is to make early cancer detection affordable, accurate, and more accessible for every adult woman.
Designed to detect cancer before mammograms can.
Non-invasive | Radiation-free | AI-driven | Results within 48 hours
A Simple Blood Test for Early Breast Cancer Detection
The ARTEMIS Test® will be a simple clinic-based blood test which aims to detect early-stage breast cancer signatures in blood plasma. It will be non-invasive, radiation-free, and complements not only existing mammography by filling the 3-year gap between screenings but also those not attending screening, as well as extending access to younger women.
Being a triage test on a positive test and discussion with their GP, patients enter the usual NHS Cancer pathway and attend clinics for mammography, ultrasound or MRI scans.
State of the art mass spectrometry instrumentation with proscribed statistical pattern recognition learning. Artemis aims to deliver results within 48 hours and with an accuracy of in excess of 95%.
The Advantage Behind The Science
Technology pioneered with the UK National Physical Laboratory
Unique pattern recognition of molecular patterns not direct detection of the circulating tumour cells (competitors use late-stage detection methods)
Clear regulatory pathway targeting UKCA, MHRA, CE and IRAS HTA clinical approvals by 2027.
Rapid turnaround:
Aiming for results in under 48 hours
State of the art instrumentation pioneered at the UK National Physical Laboratory will be used to produce the analyses
Early partnerships with UK government i.e. National Physical Laboratories, commercial clinical trial networks and UK universities
